Application of Voxtaalisib as ADV7 virus inhibitor
Voxtalisib, a dual inhibitor of PI3K and mTOR, effectively inhibits ADV7 virus replication and production, offering a promising therapeutic solution for ADV7 infections.
Patent Information
- Application Number
- CN202410992178.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-23
Smart Images

Figure CN119055654A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antiviral drugs and relates to the application of Voxtalisib in the preparation of anti-ADV7 virus drugs. Background Art
[0002] Human adenovirus type 7 (ADV7) is a widely distributed non-enveloped double-stranded DNA virus with a diameter of 90-100 nm. The capsid is dihedral and its replication is independent of host cell division. Human adenovirus (ADV) infection is very common and can cause various diseases in the human body, mainly respiratory tract infections. There are three main types of adenoviruses associated with respiratory diseases, namely ADV-3, ADV-5 and ADV-7. It is known that adenoviruses have a low risk of causing serious diseases. Commonly, it can cause acute respiratory fever, but it has a great impact on children. In severe cases, it can cause pneumonia in children. ADV7 has been confirmed to be an important cause of pneumonia in children. ADV7 can cause severe or fatal respiratory tract infections in children under 7 years old, and it is easy to cause outbreaks and endanger the health of infants and young children. At present, there is a lack of drugs with strong specificity and few side effects for ADV7 infection in clinical practice. At present, symptomatic treatment is mainly adopted. Therefore, it is imperative to develop specific drugs against ADV-7 infection.
[0003] Voxtalisib is the first oral dual inhibitor of PI3K and mTOR, with IC50 of 39, 113, 9, 43, and ~150 nM for p110α, β, γ, δ, and mTOR, respectively. In vitro, voxtalisib reduces cell viability in a concentration-dependent manner. Oral administration of voxtalisib to mice resulted in a 12-fold decrease in the number of mid-stage tumors compared with the control group. Voxtalisib has shown activity both alone and in combination with other drugs against various GBM xenografts. Voxtalisib acts on human xenografts cultured in vitro, resulting in downregulation of PI3K downstream phosphorylated proteins: pakt and ppras40, and mTOR downstream phosphorylated proteins: ps6 and p4ebp1. However, there are few reports on the use of voxtalisib for antiviral therapy.
[0004] We evaluated the inhibitory activity of voxtalisib against ADV7 virus. Summary of the invention
[0005] The purpose of the present invention is to provide Voxtalisib as an effective inhibitor of ADV7 virus in view of the above situation.
[0006] Voxtalisib (C 13 H 14 N 6O) has the following chemical structure: .
[0007] The purpose of the present invention is achieved by testing the activity of Voxtalisib using a standard viral activity test method.
[0008] Through a large number of biological experiments, the applicant found that Voxtalisib has anti-ADV7 virus activity. Specifically, it can inhibit the cytopathic effect caused by the ADV7 virus, enhance the survival rate of infected cells, inhibit the replication and proliferation of the ADV7 virus in cells, and reduce the production of progeny viruses. This shows that this compound has the potential to prepare a specific therapeutic drug for anti-ADV7 infection and has great clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 The effect of Voxtalisib on the survival rate of Hela cells treated with ADV7.
[0010] Figure 2 It is the inhibitory effect of Voxtalisib on CPE of Hela cells caused by ADV7.
[0011] Figure 3 It is the inhibitory effect of Voxtalisib on the production of ADV7 progeny virus. DETAILED DESCRIPTION
[0012] Voxtalisib used in the present invention was purchased from a reagent company.
[0013] The present invention relates to the application of Voxtalisib in preparing anti-ADV7 virus medicine.
[0014] The application refers to adding pharmaceutically acceptable excipients and carriers to Voxtalisib for the preparation of anti-ADV7 virus preparations.
[0015] The preparation is granules, tablets, pills, capsules, injections or dispersions.
[0016] Voxtalisib of the present invention has the following chemical structural formula: .
[0017] The application of Voxtalisib as an anti-ADV7 virus of the present invention has found that Voxtalisib has a significant anti-ADV7 virus effect, which indicates that this compound has the potential to prepare a specific therapeutic drug for anti-ADV7 infection and has great clinical application prospects.
[0018] The applicant has conducted an anti-ADV7 activity research experiment on the above compounds, and the experimental results are as follows: In the following, unless otherwise specified, the materials and operating methods used in the present invention are well known in the art.
[0019] 1. Test content: Analysis of compound anti-ADV7 activity: The present invention will combine cytopathic effect analysis and MTT cell viability assay to evaluate the anti-ADV7 activity of Voxtalisib.
[0020] 2. Test methods: 2.1.1 Toxicity of compounds to host Hela cells Hele cells were plated in 96-well plates and incubated at 37°C with 5% CO 2 After the incubator was full of monolayers, the cell culture medium was discarded and cell maintenance medium containing different concentrations of the test compound was added to continue the culture. After 48 h, the cytotoxicity was observed and recorded under a microscope, and the cell survival rate was determined by the MTT method. SPSS 11.5 software was used to calculate the median cytotoxic concentration (CC) of the drug for cells. 50 ). Cell survival rate = (mean OD of drug group 492 Value / average OD of cell control group 492 value) × 100%.
[0021] 2.1.2 Inhibitory activity of compounds against ADV7 HeLa cells were plated in 96-well plates and incubated at 37°C with 5% CO 2 After the incubator is full of monolayers, the culture medium is discarded, and the cells are infected with 100TCID50 ADV7 virus solution for 1.5 hours. Different concentrations of test compounds (ribavirin as a positive control drug) are added to incubate the cells. After continuing to culture for about 48 hours, when about 90% CPE lesions appear in the virus control wells, the cytopathic effect (CPE) is observed under a microscope. The observation and recording method of CPE: no cytopathic effect is recorded as -, 25% or less cytopathic effect is recorded as +, 25%-50% cytopathic effect is recorded as ++, 50%-75% cytopathic effect is recorded as +++, and 75% or more cytopathic effect is recorded as +++.
[0022] After CPE observation, the MTT method was used to detect the inhibition rate of drugs on ADV7. The specific steps were as follows: 50 μL (5 mg mL MTT) was added to each well. -1 ), incubate for 3-4 h, remove the supernatant, add an equal volume of DMSO to dissolve the precipitate. Read the corresponding absorbance (OD) at 492 nm using an enzyme reader. 492The inhibition rate of the drug on ADV7 was calculated using the following formula. The half effective concentration (EC) of the drug was calculated using SPSS 11.5 software. 50 ).
[0023]
[0024] 2.1.3 Therapeutic Index (TI) of Drugs TI = CC 50 / EC 50 The higher the therapeutic index, the greater the antiviral potential.
[0025] 3. Experimental results Table 1 Voxtalisib cytotoxicity and anti-ADV7 activity
[0026] The results of the compound cytotoxicity and anti-ADV7 activity tests are shown in Table 1. The concentration-dependent effects of the compounds on the survival rate of Hela cells acted with ADV7 are shown in Table 1. Figure 1 As shown in Figure 2, it was found that the maximum inhibition rate of Voxtalisib was about 91.1% at 25µM.
[0027] The applicant has conducted in-depth research on the anti-ADV7 activity of Voxtalisib and conducted a test on the inhibitory effect of the compound on the production of ADV7 progeny viruses. The test results are as follows: 1. Test content The inhibitory effect of the compound on the production of ADV7 progeny virus was detected after ADV7 infected Hela cells.
[0028] 2. Test methods Hela cells in logarithmic growth phase were plated in 24-well plates. After confluent monolayers, 100 TCID 50 ADV7 infected cells, incubated at 37℃ for 1.5 h, removed the virus solution, washed three times with PBS, and added cell maintenance solution containing 6.25μM concentration. After 48 h, cells and supernatant culture medium were collected, and lysed after three freeze-thaw cycles at -20℃ and 37℃. TCID 50 Methods The ADV7 virus titer was determined.
[0029] 3. Test results like Figure 2 As shown, the cell survival rate of Hela cells infected with ADV7 treated with Voxtalisib was significantly increased compared with the virus control group, indicating that the compound can significantly inhibit the activity of ADV7.
[0030] like Figure 3 As shown, the virus titer of Hela cells treated with the compound was significantly decreased compared with the virus control group, which was decreased by 4.24 log relative to the virus control.
[0031] In summary, Voxtalisib has a strong inhibitory activity against ADV7, can inhibit Hela cell death caused by ADV7 virus, and can be prepared into a clinically effective drug against ADV7 infection.
[0032] It should be understood that the above embodiments are only used to illustrate the present invention and are not used to limit the scope of protection of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the appended claims of the present application.
Claims
1. Application of Voxtalisib in anti-ADV7 virus drugs, Features: The chemical structure of Voxtalisib, a compound with anti-ADV7 activity, is shown below: 。 2. The use of Voxtalisib according to claim 1 as an anti-ADV7 virus drug, Features: Voxtalisib inhibited ADV7 by approximately 91.1% at 25µM.
3. The use of Voxtalisib according to claim 1 as an ADV7 virus inhibitor, Features: The application refers to adding pharmaceutically acceptable excipients and carriers to the compound to prepare an anti-ADV7 virus preparation.
4. The use of Voxtalisib according to claim 1 as an ADV7 virus inhibitor, Features: The preparation is in the form of granules, tablets, pills, capsules, injections or dispersions.
Citation Information
Patent Citations
Application of Voxtalisib compound in preparation of anti-EV71 virus medicine
CN113332290A
Inhibitors of MTOR kinase as anti -viral agent
US20140206678A1
Process for producing a t cell composition
US20210254000A1
Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives
WO2024083802A1
